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Abstract: Human APOBEC3 (apolipoprotein B mRNA-editing catalytic polypeptide-like 3) enzymes
are capable of inhibiting a wide range of endogenous and exogenous viruses using deaminase and
deaminase-independent mechanisms. These enzymes are essential components of our innate immune
system, as evidenced by (a) their strong positive selection and expansion in primates, (b) the evolution
of viral counter-defense mechanisms, such as proteasomal degradation mediated by HIV Vif, and
(c) hypermutation and inactivation of a large number of integrated HIV-1 proviruses. Numerous
APOBEC3 single nucleotide polymorphisms, haplotypes, and splice variants have been identified
in humans. Several of these variants have been reported to be associated with differential antiviral
immunity. This review focuses on the current knowledge in the field about these natural variations
and their roles in infectious diseases.
Keywords: APOBEC3; Polymorphism; Splice variants; HIV; HBV
1. Introduction
Human chromosome 22 codes for seven APOBEC3 enzymes (APOBEC3A/B/C/D/F/
G/H), at least four of which (APOBEC3D, APOBEC3F, APOBEC3G, and stable haplotypes
of APOBEC3H) have anti-HIV activities (reviewed in [1–7]). These innate immune enzymes
can inhibit HIV-1 replication by inflicting C > U hypermutation in viral genomes and/or
by deaminase-independent mechanisms [8–12] (Figure 1).
APOBEC3A, APOBEC3C and APOBEC3H have a single cytosine deaminase (CD)
domain. By contrast, APOBEC3B, APOBEC3D, APOBEC3F, and APOBEC3G have two CD
domains, of which only the C-terminal CD2 is catalytically active. The N-terminal CD1
domains of double-domain APOBEC3 enzymes are catalytically inactive. This is despite
the fact that both of the CD domains have the zinc-coordinating motif. The CD1 domain
plays a role in binding RNA and viral packaging of APOBEC3 enzymes. It also facilitates
ssDNA binding and is required for antiviral activity. Each of the CD1 and CD2 domains are
made of five beta sheets and six alpha helices, surrounding a zinc atom. The CD domains
have a consensus Zn-binding motif His-X-Glu-X23–28-Pro-Cys-X2–4-Cys, where X can be
any amino acid. There are three types of CD domains (Z1, Z2, and Z3), which are defined
by three specific and conserved amino acid sequences of the catalytic domain [13–18].
The main substrate for APOBEC3-induced cytosine to uracil (C > U) deamination is
single-stranded DNA (ssDNA). APOBEC3G preferentially mutates cytosine within the
CC dinucleotides of HIV-1 cDNA during reverse transcription (the targeted cytosine is
underlined). These mutations are manifested as GG > AG changes in the viral genome.
By contrast, other APOBEC3 enzymes preferentially target C within TC, which leads to
GA > AA changes in the HIV-1 genome [8,9,19,20].
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Figure 1. Inhibition of HIV-1 by APOBEC3 enzymes using deaminase-dependent and -independent
mechanisms. APOBEC3 enzymes are often counteracted by the HIV-1 Vif protein. Those not
counteracted by Vif can package into the budding virions and inhibit viral replication by inflicting
C-to-U hypermutation in the HIV-1 cDNA or by deaminase-independent mechanisms such as the
physical blockage of HIV-1 reverse transcription.
The HIV-1 protein Vif counteracts the antiviral activity of APOBEC3 enzymes. Vif
binds to APOBEC3 enzymes and mediates their ubiquitination by the cellular Cullin5 E3-
ubiquitin ligase, followed by their proteasomal degradation [4,21–24]. The counteraction
ability of Vif depends on both the type of APOBEC3 enzymes and the variations within
Vif. For instance, unlike APOBEC3G, APOBEC3F is partially resistant to neutralization
by Vif [25]. Another example is APOBEC3H haplotype II, which is highly sensitive to
the Vif variants 39F and 48H, but not the variants 39V and N48 [26–28]. These differ-
ential APOBEC3 interactions with Vif (and possibly with other HIV-1 proteins, such as
RT [11,29–31] and protease [32]) can have widely different functional consequences. The
inability to neutralize highly mutagenic APOBEC3 enzymes, such as APOBEC3G and
APOBEC3H haplotype II, often leads to the generation of inactivated HIV-1 genomes
with many C > U (G > A) changes, including stop codons [33–36]. These hypermutated
sequences are almost exclusively found as integrated proviruses that are incapable of
generating viable progeny viruses. On the other hand, the targeting of the HIV-1 genome
by less mutagenic enzymes, such as APOBEC3D and APOBEC3F, or by partially neutral-
ized APOBEC3G or APOBEC3H haplotype II, can generate sub-lethally mutated viruses.
APOBEC3-induced sub-lethal mutagenesis can contribute to HIV-1 diversification [35–39],
evolution [37,40,41], immune escape [42–44], and drug resistance [42,45–50].
The function of APOBEC3 enzymes is not limited to HIV-1 restriction. These enzymes
have also been implicated in the inhibition and/or evolution of several other viruses, [51]
such as hepatitis B virus (HBV) [52–55], polyomaviruses (e.g., JC and BK) [56,57], human
T-cell leukemia virus-1 (HTLV-1) [58,59], human papillomavirus (HPV) [60–62], and her-
pesviruses [63,64] including the Epstein–Barr virus (EBV) [65,66], herpes simplex virus-1
(HSV-1) [65], and Kaposi’s sarcoma-associated herpesvirus (KSHV) [67]. It is important to
note that data on the inhibition and hypermutation of herpesviruses by APOBEC3 enzymes
are not consistent [65,66,68,69]. Overall, unlike HIV-1, evidence for the in vivo hypermuta-
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tion of these viruses is extremely limited. Therefore, deaminase-independent mechanisms
are likely to be responsible for the inhibition of these viruses by APOBEC3 enzymes. Very
little is known about deaminase-independent mechanisms and their contributions to the
inhibition of viruses other than HIV-1. For example, APOBEC3G has been suggested
to inhibit HIV-1 reverse transcription by direct interaction with HIV-1 RT [29,30], or by
binding to viral RNA/ssDNA and limiting the movement of RT [70,71], or by reducing
tRNA annealing to HIV-1 RNA [72,73]. However, it is unclear how these processes can
inhibit DNA viruses such as HBV, polyomaviruses, and herpesviruses.
APOBEC3 enzymes have been under positive selection, and have been expanded from
one gene in mice to seven genes in primates [74–78]. Additionally, they have diversified
at both the genomic and transcriptomic levels in human populations. This is possibly in
response to exposure to different pathogens in different parts of the world [32]. Similarly,
some of the changes observed in viral genomes (e.g., HIV-1 Vif variantions V39F and N48H)
can be due to the adaptation to different APOBEC3 variants in different human popu-
lations [26–28]. These variations can underlie population-specific virus–host interaction
mechanisms. This review article focuses on human APOBEC3 variations that have been
investigated for their relevance in infectious diseases.
2. APOBEC3 Variations
APOBEC3 enzymes have many coding and noncoding variations. They are also diverse
in terms of the transcripts (splice variants) they produce. The majority of variations that have
been reported for APOBEC3 enzymes are at the DNA level, particularly single nucleotide poly-
morphisms (SNPs) [79–82]. Few studies have also investigated APOBEC3 splicing [32,83–85].
A summary of the reported variants with roles in the biology of APOBEC3 enzymes is listed
in Table 1, and the reported exonic variants are depicted in Figure 2.
2.1. APOBEC3A and APOBEC3B
APOBEC3A and APOBEC3B have been reported to play a role in the restriction and/or evo-
lution of several viruses, including HIV-1 [86–88], HBV [54,89], HPV [62,90], parvoviruses [91],
and herpesviruses [63,64,66], as well as endogenous elements including Alu [92], LINE-
1 [92,93], and HERVK [94]. These two enzymes localize to the nucleus and are expressed at
very low levels in CD4 T-cells [95]. Therefore, their potential inhibitory roles in HIV-1 infection
are likely limited to myeloid cells [88]. It is worth noting that APOBEC3A and APOBEC3B
are currently considered the main sources of TCW > TT/GW (W: T or A) mutations in many
tumors [96–98]. The main polymorphism that has been reported for APOBEC3A/B is a ~30
kb deletion, which is in high linkage disequilibrium with its surrogate SNP rs12628403 [99].
This deletion has removed all of the APOBEC3B exons and introns, except for its last exon
(exon 8), which is identical to the last exon of APOBEC3A (exon 5) [100]. Genomes with this
deletion do not express APOBEC3B mRNA, but they express a fused APOBEC3A/B mRNA,
which codes for a protein that is identical to APOBEC3A. About 40% of the world populations
are estimated to have at least one copy of this deletion, which is highly enriched in Eastern
Asian, Oceanic, and Amerindian populations [100]. The APOBEC3B deletion polymorphism
has been mostly studied in the context of HIV and HBV infections, and little is known about
the role of this deletion in other viral infections. The only exception is a co-infection study
by Prasetyo et al., in which an analysis of 597 HIV-1-positive samples from Indonesian pop-
ulations showed higher rates of co-infection by HBV, HCV, TTV (torque teno virus), and
Toxoplasma gondii in individuals with an APOBEC3B deletion genotype [101]. HBV studies
are limited, but overall, they seem to suggest little/no difference in the HBV disease risk
among people with and without APOBEC3B. For instance, a study of 724 HBV carriers and
469 healthy subjects showed neither an association between the APOBEC3B deletion and
HBV infection status, nor with the extent of viral hypermutation [102]. Similarly, a study of
179 chronic HBV patients and 216 healthy Moroccan donors did not show a difference in
the frequency of APOBEC3B deletion between the healthy and disease groups. However,
individuals having the deletion genotype showed a faster progression to liver diseases [103].
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Table 1. Summary of APOBEC3 variations and their effects.







~30 kb deletion (∆) of all
APOBEC3B exons and introns









PMID: 26305823 HIV-1 co-infections: ∆ > reference
Moroccan
PMID: 24010642
%∆: HBV patients ~ healthy donors
Progression to liver diseases: ∆ > reference
Western Indian




HIV-1 acquisition, progression to AIDS, and viral set
point: ∆/∆ > reference
Japanese and Indian
PMID: 20684727 %∆: HIV-1 patients ~ healthy donors
Japanese
PMID: 19788695
%∆: HBV patients ~ healthy donors
Hypermutation context: ∆ ~ reference
Japanese
PMID: 24667791
%∆: HIV-1 patients ~ healthy donors
HIV-1 co-infections: ∆ ~ reference


































PMID: 30660178 %G (238A): HIV-1 patients > 1000 Genomes Africans
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PMID: 30660178 %T (97C): HIV-1 patients > 1000 Genomes Africans
PMID: 23755966
Protein expression: R ~ C
Anti-HIV-1 activity: R > C
Sensitivity to HIV-1 Vif: R ~ C















Protein expression: R > K
Anti-HIV-1 activity: R > K
Sensitivity to HIV-1 Vif: R ~ K




















































Set-point viral load: I > V
Progression to AIDS: I > V
Pneumocystis pneumonia: I > V
PMID: 30448640
HIV-1 restriction: V > I
Protection against HIV-1 Vif: V > I
Level of viral encapsidation: V > I
APOBEC3F∆2 Isoform lacking exon 2 PMID: 20624919
Sensitivity to Vif: main isoform > APOBEC3F∆2
Viral packaging: main isoform > APOBEC3F∆2
Antiviral activity: main isoform > APOBEC3F∆2
Deamination: main isoform > APOBEC3F∆2
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Table 1. Cont.
Description Allelic Frequency Studied Populations andReferences Effect
African European Asian
APOBEC3F
APOBEC3F∆2-4 Isoform lacking exons2, 3 and 4 PMID: 20624919
Sensitivity to Vif: APOBEC3F∆2–4 > main isoform
Viral packaging: main isoform > APOBEC3F∆2–4
Antiviral activity: Main isoform > APOBEC3F∆2–4


















Susceptibility to HIV-1 infection: G ~ C
Brazilian
PMID: 20874421 CD4 T-cell count: CC > CG and GG
West Indian
PMID: 29864532
%CG: HIV patients > healthy donors
%(GC + CC): HIV patients > healthy donors
Zimbabwean


































Susceptibility to HIV-1 infection: C ~ G
West Indian
PMID: 29864532
%CG: HIV-1 patients > healthy donors
%GG: healthy donors > HIV patients
Zimbabwean
PMID: 27245545 Susceptibility to HIV-1 infection: C ~ G
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Susceptibility to HIV-1 infection: T ~ C
Diverse populations
PMID: 23138837
HIV-1 disease progression: T > C

















Susceptibility to HIV-1 infection: T ~ C
Zimbabwean

















Susceptibility to HIV-1 infection: C ~ G
Progression to AIDS: G > C
Zimbabwean

















Susceptibility to HIV-1 infection: H ~ R
Rate of CD4 T cell loss: R > H
Progression to AIDS: R > H
PMID: 27064995 Antiviral activity: H > RCounteraction by Vif: H ~ R
Diverse populations
PMID: 23138837
HIV-1 disease progression: R > H
CNS impairment: R > H
South Africans
PMID: 19996938
Viral load: R > H
CD4 T cell count: H > R
French
PMID: 15609224 Progression to AIDS: H ~ R
Caucasians
PMID: 16988524 Progression to AIDS: H ~ R
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Progression to AIDS: H ~ R
Viral G-to-A mutation: H ~ R
Argentinian
PMID: 21571098
HIV-1 transmission: H ~ R
Progression to AIDS: H ~ R
Viral G-to-A mutation: H ~ R
Zimbabwean
PMID: 27245545 Susceptibility to HIV-1 infection: H ~ R
Morocco
PMID: 24010642 Risk of HBV acquisition: H ~ R
Burkina Fasoian
PMID: 26741797
Protection against HIV-1 infection: GGT [rs6001417,
rs8177832 (H186R), rs35228531] > Other haplotypes




HIV-1/HBV co-infection rate: other haplotypes > GGT
[rs6001417, rs8177832 (H186R), rs35228531]
Western Indian
PMID: 26853443
Risk of HIV-1 acquisition: H ~ R
Progression to AIDS: H ~ R
North Indian















PMID: 16988524 Risk of HIV-1 infection: T > C
Argentinian
PMID 22145963
Progression to AIDS: H ~ R
Viral G > A mutation: H ~ R
Argentinian
PMID: 21571098
HIV-1 transmission: H ~ R
Progression to AIDS: H ~ R
Viral G-to-A mutation: H ~ R
C > T polymorphism was associated with Vif variation.
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PMID: 16988524 Risk of HIV-1 infection: C ~ G
Northern South African















Protection against HIV-1 infection: GGT [rs6001417,
rs8177832 (H186R), rs35228531] > Other haplotypes




HIV-1/HBV co-infection rate: other haplotypes > GGT















Viral load: T > C
CD4 T-cell count: C > T
Burkina Fasoian
PMID: 26741797
Protection against HIV-1 infection: GGT [rs6001417,
rs8177832 (H186R), rs35228531] > Other haplotypes




HIV-1/HBV co-infection rate: C > T
HIV-1/HBV co-infection rate: Other haplotypes > GGT
[rs6001417, rs8177832 (H186R), rs35228531]











PMID: 16940537 HIV-1 hypermutation: C > T
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PMID: 32235597 Antiviral activity: Reference > ∆
Northern South African
PMID: 30660178 %∆: HIV-1 patients >1000 Genomes Africans
Japanese
PMID: 25721876 Susceptibility to HIV-1 infection: ∆ > reference
Indian





























PMID: 32235597 Ubiquitination: G (HapI) > R (HapII)
PMID: 20519396
Antiviral activity: R (HapII) > G (HapI)
HIV-1 encapsidation: R (HapII) ~ G (HapI)
Protein expression: R (HapII) > G (HapI)
Interaction with Gag: R (HapII) with nucleocapsid; G




Susceptibility to HIV-1 infection: G (HapI) > R (HapII)
Progression to AIDS: G (HapI) > R (HapII)
Indian
PMID: 26559750 %15∆-105R: HIV-1 patients > healthy donors
Diverse populations















PMID: 21167246 Rate of HIV-1 GA-to-AA mutation: D (HapII) > K (HapI)
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PMID: 21167246 Rate of HIV-1 GA-to-AA mutation: D (HapII) > E (HapI)
Northern South African
PMID: 30660178 %C (178D): HIV-1 patients > 1000 Genomes Africans
PMID: 27534815
Cytosine deamination: E (HapV) > D (other haplotypes)
Methyl cytosine deamination: D (HapII) >> E
(other haplotypes)












PMID: 30297863 %SV200: ∆ > CTC
SV200, SV183,
SV182, and SV154
Splice variants with different
C-terminals
Diverse populations
PMID: 18945781 Viral restriction: SV200 (HapII) > other variants
Diverse populations
PMID: 30297863
Antiviral activity: HapII-SV200 > SV182/183
Viral encapsidation: HapII-SV182/183 > SV200
Protease processing: only HapII SV200
L1 fragment in transcript: only HapII SV200
PMID: 27534815 Cytosine and methyl cytosine deamination:HapI-SV182/183 > SV200 >> SV154
PMID: 31400856 HBV restriction: HapII SV183 > other variants




Figure 2. A schematic of main human APOBEC3 variantions shown on (A) human chr22 and (B) the available human
APOBEC3 structures. The catalytic domains Z1, Z2, and Z3 are colored in green, orange, and blue, respectively.
In contrast with HBV, data on HIV-1 are inconsistent. A study of 150 HIV-infected
patients and 150 healthy donors in Western India showed a lower risk of HIV-1 acquisi-
tion in the donors with no APOBEC3B deletion [104]. Similar results were reported in a
study including over 4000 donors from five HIV-1 cohorts. This study, which was con-
ducted using samples from European Americans and African Americans, found no effect
associated with the heterozygous APOBEC3B deletion, but reported direct associations
between homozygous deletion and HIV-1 acquisition, progression to AIDS, and viral set
point [105]. By contrast, other studies have found no evidence for such associations. For
example, Itaya et al. analyzed the data from previously reported Japanese and Indian
populations [106] and did not observe a difference in the frequencies of the APOBEC3B
deletion allele between the HIV-1-infected and control subjects [107]. The analysis of a
cohort of Japanese MSM (men who have sex with men), including 248 HIV-1-infected
patients and 207 uninfected donors, reached a similar conclusion. The study found no
difference between the infected and uninfected men in terms of their APOBEC3B genotype
composition. Additionally, the authors reported no difference in the rates of co-infections
by HBV, HCV, and syphilis between the two groups. Furthermore, no difference was
observed in disease progression parameters, and PBMCs from the infected and uninfected
groups were shown to have comparable susceptibility to HIV-1 infection [108]. Overall,
studies on the role of the APOBEC3B deletion polymorphism in the susceptibility to HIV
acquisition, rates of co-infections, and disease progression have returned different results.
Given that APOBEC3B localizes to the nucleus and is not expressed in CD4 T-cells, this
enzyme is expected to have little/no impact on the HIV-1 disease status. The reason for the
observed associations is not clear.
2.2. APOBEC3C
APOBEC3C is expressed at high levels in many tissues and cell types [95,109], and
in vitro studies have shown that it can partially inhibit LINE-1 retrotransposition [110,111].
This enzyme localizes to the nucleus, and, except for its rare variant I188, it has weak/no
antiviral activity against exogenous viruses. A change from serine (S) to isoleucine (I)
in this position (S188I), which is frequent in sub-Saharan African populations, enhances
the anti-HIV activity of APOBEC3C in vitro [112,113]. Nevertheless, compared to other
APOBEC3 enzymes, such as APOBEC3G and APOBECH, this APOBEC3C variant has lim-
ited mutagenic activity. Therefore, it has been postulated that APOBEC3C can potentially
play a role in HIV-1 diversification [113].
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2.3. APOBEC3D
There are not many coding variations within APOBEC3D; therefore, studies focusing
on APOBEC3D variations are limited. There is currently no crystal structure available for
this enzyme. APOBEC3D localizes to the cytosol and is capable of hypermutating the HIV-1
genome; however, its deaminase activity is limited compared to APOBEC3F, APOBEC3G,
and the stable haplotypes of APOBEC3H [9,37,114–116]. This enzyme has been suggested
to play a role in HIV-1 diversification [37]. Matume et al. analyzed the APOBEC3 poly-
morphism in 192 HIV-1-infected patients in Northern South Africa, and compared the
genotype composition of this cohort with those of the HapMap, 1000 Genomes Project,
and ExAC donors [80]. The study identified several variants of APOBEC3D, APOBEC3F,
APOBEC3G, and APOBEC3H. The APOBEC3D variants R97C and T238A were reported to
be more frequent in the HIV-1-infected cohort than in the African population of the 1000
Genomes Project. Importantly, a study by Duggal et al. showed that the R97C and R248K
variants of APOBEC3D have significantly lower antiviral activities against HIV-1∆vif [117].
The study also showed that these two variants, which are specific to sub-Saharan African
populations, were highly sensitive to HIV-1 Vif. The variant R248K also showed decreased
anti-Alu activity; however, no anti-Alu activity difference was found for R97C. The authors
associated this global reduction in the antiviral activity of the R248K mutant to its reduced
expression [117].
2.4. APOBEC3F
Human APOBEC3F has been shown to inhibit HIV-1 via both deaminase and deaminase-
independent mechanisms, although there is growing evidence suggesting the latter is the
primary mechanism of viral inhibition [118–123]. APOBEC3F is less mutagenic compared
to APOBEC3G, and can induce HIV-1 evolution and drug escape [35,37,124]. Not much is
known about the role of this enzyme in inhibiting other viruses. A study by Matume et al.
showed that the APOBEC3F variants A108S and Y307C were more frequent in a cohort
of HIV-1-infected patients in Northern South Africa than the African populations of the
1000 Genomes Project [80]. To investigate the role of APOBEC3F variations in the suscep-
tibility to HIV-1 acquisition and disease progression, An et al. performed a large-scale
association analysis, using data from six pretreatment HIV/AIDS cohorts (n = 4203) [125].
The study included 707 European American and 281 African American incident serocon-
verters, 1135 uninfected but at risk individuals, and 2076 previously infected donors. The
presence of valine (V) instead of isoleucine (I) in APOBEC3F position 231 (rs2076101) was
reported to be associated with a lower set-point viral load, slower progression to AIDS, and
delayed development of pneumocystis pneumonia [125]. In vitro experiments suggested
that variations in this amino acid position influence the HIV-1 Vif-mediated degradation
of APOBEC3F [125]. In a separate study, the variant 231V was shown to increase HIV-1
restriction by APOBEC3F. The authors suggested that the effect was due to an increase in
APOBEC3F steady-state levels, and, therefore, partial protection of APOBEC3F from degra-
dation mediated by HIV-1 Vif [126]. Importantly, this variant is highly abundant in African
populations and data suggest it has an increased level of viral encapsidation [126]. Overall,
rs2076101 (V231I) seems to be the only APOBEC3F SNP whose differential protective effect
is reported in different studies. A study by Lassen et al. has shown that APOBEC3F mRNA
splicing also plays a role in the antiviral activity of this enzyme [84]. Using PBMCs from
ten healthy donors, the study identified two APOBEC3F splice variants with different
expression levels in different cell types. One isoform, which is resistant to Vif, lacks exon 2
(APOBEC3F ∆2) and is expressed in macrophages and monocytes. The other isoform lacks
exons 2, 3, and 4 (APOBEC3F ∆2–4) and is very sensitive to Vif-mediated degradation.
Compared to the main APOBEC3F isoform, these two splice variants showed reduced viral
encapsidation, antiviral activity, and mutagenicity [84].
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2.5. APOBEC3G
The majority of hypermutated HIV-1 sequences have a GG > AG mutation signature,
which is attributed to APOBEC3G. This enzyme is a potent antiviral protein and therefore
has been studied by many investigators in the field (reviewed in [1,4,8,127]). APOBEC3G
also inhibits other viruses, such as HBV [128,129], HTLV-1 [58,59], and Alu [130]. Sev-
eral coding and non-coding variants have been reported for this enzyme, however, the
most studied variation is H186R (rs8177832). It has been shown that the variant 186R
has lower antiviral activity compared to 186H [131]. The variant 186H is prevalent out-
side of Africa, and 186R is mostly present in sub-Saharan African populations. An et al.
genotyped 3073 donors from six HIV–AIDS cohorts and found seven SNPs, including
H186R [79]. Three of these SNPs are upstream of APOBEC3G, with potential regulatory
roles (-571G/C (rs5757463), -199G/A (rs34550797), and -90C/G (rs5750743)), two are within
introns (197193T/C (rs3736685) and 199376G/C (rs2294367)), and two are within exons
(F119F (rs5757465) and H186R (rs8177832)). The 186R variant was found to be associated
with a decline in the number of CD4 T-cells and an accelerated progression to AIDS [79].
These findings were confirmed in a study of 1049 children with symptomatic HIV-1 in-
fection, who were enrolled in Pediatric AIDS Clinical Trial Group (PACTG) [132]. The
participants in that study were 60% black, 26% Hispanic, 13% white, and 1% unknown
ethnicity. The APOBEC3G homozygous 186R/R variant was reported to be associated with
rapid HIV-1 disease progression and central nervous system impairment. Additionally,
the C allele of F119F was found to be associated with protection against disease progres-
sion [132]. However, a study focused on a French cohort of 327 HIV-1 patients with extreme
disease progression phenotypes and 446 healthy subjects did not show such associations,
neither for H186R nor for any of the other reported SNPs [133]. This association was also
not observed in a study conducted in Montreal, on samples from Caucasians exposed
to HIV-1 [134]. A total of 69 individuals infected with HIV-1, by homosexual contact or
drug injection, and 53 exposed seronegative individuals from the same exposed cohort
were included in that study. The authors identified several SNPs in their cohort, but none
except for an intronic SNP (C40693T, rs17496018) was associated with an increased risk of
HIV-1 infection. The variant Q275E (rs17496046) was among the SNPs that did not show
an association in Caucasians [134]. By contrast, Matume et al. reported that Q275E is more
frequent in a cohort of HIV-1-infected patients in Northern South Africa than in the African
populations of the 1000 Genomes Project [80]. The polymorphisms H186R and C40693T
(rs17496018) were also studied in two papers by De Maio et al., using samples from 534 chil-
dren who were perinatally exposed to HIV-1 [135,136]. The studies did not identify an
association between the APOBEC3G polymorphism and the transmission or progression
to pediatric AIDS. Also, no association was found between APOBEC3G variations and the
level of G > A mutations in viral genomes. However, C40693T (rs17496018) was reported
to be associated with changes in the Vif motifs that interact with APOBEC3G.
The APOBEC3G coding variation H186R has also been studied by several other
groups, but, overall, the results are inconsistent. For example, Singh et al. compared
153 HIV patients with 156 healthy controls in Western India and found no homozygous
RR donors in either group [137]. The study found 13% H/R heterozygosity in the healthy
donor group and none in the HIV group. This is different from a study involving North
Indian donors, which did not find a single 186R variant among a total of 560 subjects
studied (50 HIV-1-exposed seronegative donors, 320 HIV-1 seronegative healthy subjects,
and 190 HIV-1 seropositive patients) [138]. The observed discrepancies might be due to
differences in the studied populations and the overall low frequencies of minor variants.
Most of the APOBEC3G variants, including H186R and Q275E, are highly population-
specific and their minor variants are mostly found in people with a sub-Saharan African
origin. The frequencies of these minor variants are negligible in other populations [132].
This raises the possibility that studies focusing on non-African populations might not have
enough statistical power to detect associations between these SNPs and disease status.
Viruses 2021, 13, 1366 15 of 24
In a study by Reddy et al., the role of APOBEC3G expression and polymorphisms in
HIV-1 susceptibility and early disease pathogenesis was investigated using samples from
250 South African women who were at high risk of HIV-1 infection [139]. The authors found
that within the first 12 months of infection, HIV-positive donors have significantly lower
levels of APOBEC3G mRNA than HIV-negative donors. This trend was also observed when
within-patient pre- and post-infection samples were analyzed. However, the study found
no association between APOBEC3G mRNA levels and viral loads or CD4 T-cell counts in
the 32 seroconverters studied, or in the donors who were consistently seronegative. Among
the twenty-four APOBEC3G genetic variants identified in this cohort, rs8177832 (H186R)
and a downstream variant rs35228531 (C > T) showed strong associations with high viral
loads and low CD4 T-cell counts [139]. Compaore et al. also investigated three of these
APOBEC3G variants, but using a cohort of 336 seropositive and 372 seronegative donors
from Burkina Faso [140]. It was shown that these variants are genetically linked and the
haplotype GGT (rs6001417, rs8177832 (H186R), and rs35228531, respectively) has a protec-
tive effect. By contrast, the haplotypes GGC and CGC were associated with an increased
risk of HIV-1 infection. The same team also studied the role of these variants in HBV/HIV
co-infection [141]. The T minor allele of rs35228531 was found to be protective against
HBV/HIV co-infection, and among the reported haplotypes, only GGT was protective. By
contrast, in a study of 179 HBV chronic carriers and 216 healthy donors in Morocco, the
polymorphism H186R was shown to be irrelevant in HBV acquisition [103].
In addition to the above-mentioned coding SNPs and their linked non-coding variants,
several other SNPs within APOBEC3G introns and its upstream/downstream regions have
been reported. Again, the results appear to be population-dependent. For example, a study
of 400 therapy-naïve HIV-1-infected patients from Brazil showed that the CC homozygous
genotype of an SNP upstream of APOBEC3G (rs5757463, C/G) was associated with an
increased CD4 T-cell count. The donors with CG and GG genotypes showed lower CD4
T-cell counts. The study did not find any other associations in the APOBEC3G locus [142].
This SNP and another upstream SNP (rs5750743, C/G) were investigated in 153 HIV-1
patients and 156 healthy donors from India. It was shown that the heterozygous CG
genotypes for both SNPs were more frequent in the HIV-1 group than the control group.
The GG genotype for the SNP rs5750743 was less frequent in the HIV-1 group, and the
dominant CG + CC genotype for the SNP rs5757463 occurred at a higher level in the
HIV-1 patients [143]. These SNPs and several other noncoding SNPs were also studied in a
Zimbabwean pediatric population, to investigate the role of APOBEC3G polymorphisms
in the susceptibility to HIV infection among children who were born to HIV-infected
mothers [144]. The study, which involved 104 children aged 7–9 years, did not find
any associations between those APOBEC3G variations (or their combinations as part of
haplotypes) and HIV susceptibility. Finally, an analysis of the association between the
APOBEC3 polymorphism and HIV-1 subtype B hypermutation in a West Australian HIV
cohort (n = 127) showed a marginal association for the intronic SNP rs5757467 [145].
2.6. APOBEC3H
APOBEC3H is the most variable member of the APOBEC3 family. This protein has the
following five major non-synonymous variations: N15∆ (rs140936762), R18L (rs139293),
G105R (rs139297), K121D (rs139299 and rs139298), and E178D (rs139302), collectively cod-
ing for at least 13 protein haplotypes with diverse geographic distributions (Figure 3A,B).
Four of these haplotypes (I–IV) have an allelic frequency of >1%. The haplotypes II (NR-
RDD), V (NRRDE), and VII (NRRKE) show strong antiviral activities [32,83,85,146,147].
Variants with a deletion in position 15 and/or G in position 105 are unstable and have
little/no antiviral activity, likely due to ubiquitination [148]. Differential interactions with
HIV-1 Gag have also been suggested to be responsible for the significantly reduced antiviral
activity of HapI, which has a G in position 105 [149]. APOBEC3H HapII interacts with the
nucleocapsid in an RNA-dependent manner, but APOBEC3H HapI interacts with the C-
terminus of the matrix and the N-terminus of capsid proteins. Therefore, incorporation into
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the viral core is essential for the antiviral activity of APOBEC3H [149]. Nuclear localization
of APOBEC3H HapI has also been suggested to explain its reduced antiviral activity [81].
Figure 3. APOBEC3H variations. (A) Main APOBEC3H haplotypes, splice variants, and protein variants; (B) geographic
distribution of main APOBEC3H haplotypes; (C) a schematic of population-specific APOBEC3H mRNA splicing, HIV-1
protease processing of SV200 into SV186, and adaptation of HIV-1 Vif to HapII.
Gourraud et al. genotyped APOBEC3H in 96 HIV-1-infected therapy-naïve patients,
and showed that a cluster of SNPs (rs139316, rs139317, rs139323, and rs139336), which are
genetically linked to the known SNPs G105R, K121D, and E178D are associated with differ-
ences in GA > AA hypermutation and viral RNA levels [150]. It is known that the HIV-1 Vif
amino acid positions 39 and 48 play a key role in APOBEC3H counteraction, and changes
in these two positions are linked to the APOBEC3H genotype of patients [26–28,151,152].
Ooms et al. determined the APOBEC3H haplotypes and HIV-1 Vif sequences in 76 infected
patients, and found higher viral loads and lower CD4 T-cell counts in patients who were
homozygous for unstable APOBEC3H haplotypes. Their study showed an enrichment of
phenylalanine (F) at the Vif amino acid position 39 in donors with a stable APOBEC3H
haplotype, compared to those with unstable APOBEC3H variants. A mutation of pheny-
lalanine (F) to valine (V) abolished the ability of Vif to counteract APOBEC3H [27]. The
Vif variants 39F and 48H can degrade stable APOBEC3H enzymes, and are referred to
as ‘hyper-Vif’. Other variants (39 V and 48 N), which do not counteract APOBEC3H,
are known as ‘hypo-Vif’ [26,27]. Refsland et al. used hyper-Vif and hypo-Vif variants
of HIV-1 to infect primary cells with different APOBEC3H haplotypes. All the viruses
replicated in cells with unstable APOBEC3H haplotypes I, III, and IV, but only hyper-Vif
HIV-1 showed robust replication in cells with stable APOBEC3H haplotypes (Haps II
and V). Importantly, the study found a positive correlation between the prevalence of
hyper-Vif HIV-1 isolates and the allelic frequency of APOBEC3H stable haplotypes across
the globe [26]. This selective pressure on the HIV-1 Vif, imposed by APOBEC3H, has
been confirmed in a humanized mouse model [28]. Altogether, these data suggest that
HIV Vif adapts to stable and restrictive variants of APOBEC3H. Interestingly, a study by
Benito et al. reported that the frequencies of unstable APOBEC3H haplotypes (those with
15∆ and 105G) were lower in HIV-1 elite controller (EC) patients than non-controller (NC)
donors (23/30 = 77% EC vs. 10/11 = 91% NC) [153]. The overall high percentages of
unstable APOBEC3H haplotypes in this Spanish cohort is not unexpected, because the
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stable haplotypes of APOBEC3H (II, V, and VII) are mostly found in people of sub-Saharan
African origin. Two studies focusing on Japanese and Indian populations showed that
the variations 15∆ and 105G, which make APOBEC3H unstable, are associated with the
susceptibility to HIV-1 infection [154,155]. Additionally, a study by Matume et al. showed
that the APOBEC3H variants N15∆, R18L, G105R, and E178D are found more frequently
in a cohort of HIV-1-infected patients in Northern South Africa compared to the African
populations of the 1000 Genomes Project [80].
Four splice variants (SV200/183/182/154) have been reported for APOBEC3H, three
of which (SV200, SV183, and SV182) show antiviral activity [32,83] (Figure 3A). Harari
et al. analyzed the PBMCs from 12 healthy donors, and showed that all of the APOBEC3H
haplotypes I–IV were resistant to Vif. The authors tested the antiviral and deaminase
activities of different APOBEC3H splice variants using haplotypes I and II expression
vectors, and found that all of the HapII splice variants were significantly more antiviral
than those of HapI. Overall, HapII SV200 showed slightly more antiviral and deaminase
activities than Hap II SV182/3 [83]. Gu et al. expanded this work, and they studied all
four splice variants and seven haplotypes I-VII of APOBEC3H. The haplotypes II, V, and
VII were shown to have high cytosine deamination activity. Additionally, it was shown
that these haplotypes, particularly HapII, also target methylated cytosines for deamination.
The deaminase activity of these variants were correlated with their anti-HIV activity [85].
Gu et al. only investigated the HapI version of the APOBEC3H splice variants, and
observed that HapI SV200 had lower enzymatic activity compared to other HapI isoforms.
Interestingly, on a HapII backbone, this trend is reversed, and HapII SV200 shows the
highest antiviral activity [32,83]. Data on the role of these splice variants in inhibiting other
viruses are limited, but HapII SV183 has been shown to have the highest antiviral activity
against HBV [55].
In addition to exonic variations, APOBEC3H has an intronic indel polymorphism
(CTC/∆, rs149229175) that alters mRNA splicing [32]. Similar to other APOBEC3H genetic
variations, this SNP is highly population-specific. The CTC deletion is almost exclusively
embedded in the HapII genome, which is present (at least one copy) in ~80% of sub-Saharan
African populations. The CTC deletion induces the inclusion of an intronic antisense L1
element as a new exon (exon 4b) in APOBEC3H HapII mRNA. The result of this L1
exonization is a new splice variant (SV200) with an extended and different C-terminus.
Importantly, the C-terminus tail of SV200 is cleaved by the HIV-1 protease, to form a new
variant with 186 amino acids (SV186), with reduced antiviral activity [32] (Figure 3C).
3. Future Directions and Conclusions
The studies of APOBEC3 variations have mostly focused on genetic variations. Nu-
merous polymorphic sites have been reported for APOBEC3 enzymes, particularly for
APOBEC3G, which is known for its potent anti-HIV activity, and APOBEC3H, which is
known for its high diversity. Variations in both the APOBEC3 gene bodies and regulatory
regions have been shown to play a role in the biology of APOBEC3 enzymes and their
interaction with viruses such as HIV-1 and HBV. However, the molecular mechanisms un-
derlying the observed differences associated with APOBEC3 genetic variations are mostly
unknown. For example, it is not clear why the carriers of the APOBEC3G 186R variant
progress to AIDS faster. The evolutionary origin of APOBEC3 variations and the selection
forces diversifying APOBEC3 enzymes in different human populations are also mostly
unknown. As an example, it is unclear what led to APOBEC3H diversification, to the extent
that three of its main haplotypes, Haps I, III, and IV, lost their antiviral activities. These
unstable haplotypes account for ~77% of all APOBEC3 variants in human populations, yet
little is known about their roles. Strikingly, the APOBEC3H haplotypes III and IV, despite
being genetically similar, have widely different geographic distributions. APOBEC3H
HapIII is prevalent in sub-Saharan African populations and APOBEC3H HapIV is mostly
found outside of Africa. This might be to a genetic bottleneck, or possibly a selection
mechanism, which is yet to be studied and identified. APOBEC3 genes are coded in
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tandem on chromosome 22, and form haplotype blocks extending across two or more
APOBEC3 genes. Also, due to their close proximity, a considerable amount of splicing
occurs between the exons of adjacent APOBEC3 genes. Currently, little is known about
these APOBEC3 genomic and transcriptomic interdependences, and their roles in viral
hypermutation and inhibition. Mutation of viruses by APOBEC3 enzymes can have widely
different functional consequences, depending on the genetic makeup of both the patient
and the virus. Too much cytosine deamination by potent APOBEC3 enzymes, such as
APOBEC3G and APOBEC3H HapII, can be lethal to the virus. This is particularly true for
stop codons, which are generated at a higher rate by APOBEC3G (GG > AG) compared to
other APOBEC3 enzymes (GA > AA). By contrast, sublethal mutations have been shown
to drive viral diversification and drug escape. It is not clear what APOBEC3 enzymes
and variants are responsible for lethal versus sublethal viral mutations, and whether these
play a role in donor-specific and/or and population-specific responses to infection and
antiviral therapies. Most of these key questions are cross-disciplinary by nature, and
they require extensive collaborations among wet-lab and quantitative scientists to answer.
More importantly, they require data sharing, something that is still not practiced by many
scientists in the field. It is very unfortunate that, despite many datasets generated from
studies of elite controller HIV-1 patients, little is publicly available. Overall, there is a lot to
learn about differential antiviral immunity in humans by studying APOBEC3 variations,
and this provides ample opportunities for research and training across quantitative and
experimental biosciences.
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110. Muckenfuss, H.; Hamdorf, M.; Held, U.; Perković, M.; Löwer, J.; Cichutek, K.; Flory, E.; Schumann, G.G.; Münk, C. APOBEC3
Proteins Inhibit Human LINE-1 Retrotransposition. J. Biol. Chem. 2006, 281, 22161–22172. [CrossRef]
111. Horn, A.V.; Klawitter, S.; Held, U.; Berger, A.; Vasudevan, A.A.J.; Bock, A.; Hofmann, H.; Hanschmann, K.-M.O.; Trösemeier, J.-H.;
Flory, E.; et al. Human LINE-1 restriction by APOBEC3C is deaminase independent and mediated by an ORF1p interaction that
affects LINE reverse transcriptase activity. Nucleic Acids Res. 2014, 42, 396–416. [CrossRef]
112. Wittkopp, C.J.; Adolph, M.B.; Wu, L.I.; Chelico, L.; Emerman, M. A Single Nucleotide Polymorphism in Human APOBEC3C
Enhances Restriction of Lentiviruses. PLoS Pathog. 2016, 12, e1005865. [CrossRef] [PubMed]
113. Anderson, B.D.; Ikeda, T.; Moghadasi, S.A.; Martin, A.S.; Brown, W.L.; Harris, R.S. Natural APOBEC3C variants can elicit
differential HIV-1 restriction activity. Retrovirology 2018, 15, 78. [CrossRef] [PubMed]
114. Refsland, E.W.; Hultquist, J.F.; Harris, R.S. Endogenous Origins of HIV-1 G-to-A Hypermutation and Restriction in the Nonper-
missive T Cell Line CEM2n. PLoS Pathog. 2012, 8, e1002800. [CrossRef] [PubMed]
115. Chaipan, C.; Smith, J.L.; Hu, W.-S.; Pathak, V.K. APOBEC3G Restricts HIV-1 to a Greater Extent than APOBEC3F and APOBEC3DE
in Human Primary CD4+ T Cells and Macrophages. J. Virol. 2012, 87, 444–453. [CrossRef] [PubMed]
Viruses 2021, 13, 1366 23 of 24
116. Gillick, K.; Pollpeter, D.; Phalora, P.; Kim, E.-Y.; Wolinsky, S.; Malim, M.H. Suppression of HIV-1 Infection by APOBEC3 Proteins
in Primary Human CD4+ T Cells Is Associated with Inhibition of Processive Reverse Transcription as Well as Excessive Cytidine
Deamination. J. Virol. 2013, 87, 1508–1517. [CrossRef] [PubMed]
117. Duggal, N.K.; Fu, W.; Akey, J.M.; Emerman, M. Identification and antiviral activity of common polymorphisms in the APOBEC3
locus in human populations. Virology 2013, 443, 329–337. [CrossRef] [PubMed]
118. Holmes, R.K.; Koning, F.A.; Bishop, K.N.; Malim, M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription
products in the absence of hypermutation—Comparisons with APOBEC3G. J. Biol. Chem. 2007, 282, 2587–2595. [CrossRef]
119. Krisko, J.F.; Begum, N.; Baker, C.E.; Foster, J.L.; Garcia, J.V. APOBEC3G and APOBEC3F Act in Concert to Extinguish HIV-1
Replication. J. Virol. 2016, 90, 4681–4695. [CrossRef]
120. Jonsson, S.R.; Hache, G.; Stenglein, M.D.; Fahrenkrug, S.C.; Andresdottir, V.; Harris, R.S. Evolutionarily conserved and non-
conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res. 2006, 34, 5683–5694. [CrossRef]
121. Ara, A.; Love, R.P.; Follack, T.B.; Ahmed, K.A.; Adolph, M.B.; Chelico, L. Mechanism of Enhanced HIV Restriction by Virion
Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G. J. Virol. 2017, 91. [CrossRef] [PubMed]
122. Mbisa, J.L.; Bu, W.; Pathak, V.K. APOBEC3F and APOBEC3G Inhibit HIV-1 DNA Integration by Different Mechanisms. J. Virol.
2010, 84, 5250–5259. [CrossRef]
123. Adolph, M.B.; Ara, A.; Chelico, L. APOBEC3 Host Restriction Factors of HIV-1 Can Change the Template Switching Frequency of
Reverse Transcriptase. J. Mol. Biol. 2019, 431, 1339–1352. [CrossRef] [PubMed]
124. Mohammadzadeh, N.; Love, R.P.; Gibson, R.; Arts, E.J.; Poon, A.F.; Chelico, L. Role of co-expressed APOBEC3F and APOBEC3G
in inducing HIV-1 drug resistance. Heliyon 2019, 5, e01498. [CrossRef]
125. An, P.; Penugonda, S.; Thorball, C.W.; Bartha, I.; Goedert, J.J.; Donfield, S.; Buchbinder, S.; Binns-Roemer, E.; Kirk, G.D.;
Zhang, W.; et al. Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia. PLoS Genet.
2016, 12, e1005921. [CrossRef]
126. Mohammadzadeh, N.; Follack, T.B.; Love, R.P.; Stewart, K.; Sanche, S.; Chelico, L. Polymorphisms of the cytidine deaminase
APOBEC3F have different HIV-1 restriction efficiencies. Virology 2019, 527, 21–31. [CrossRef]
127. Malim, M.H. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos. Trans. R. Soc. B Biol. Sci. 2008, 364, 675–687.
[CrossRef]
128. Noguchi, C.; Hiraga, N.; Mori, N.; Tsuge, M.; Imamura, M.; Takahashi, S.; Fujimoto, Y.; Ochi, H.; Abe, H.; Maekawa, T.; et al. Dual
effect of APOBEC3G on Hepatitis B virus. J. Gen. Virol. 2007, 88, 432–440. [CrossRef]
129. Lei, Y.C.; Hao, Y.H.; Zhang, Z.M.; Tian, Y.J.; Wang, B.J.; Yang, Y.; Zhao, X.P.; Lu, M.J.; Gong, F.L.; Yang, D.L. Inhibition of hepatitis
B virus replication by APOBEC3G in vitro and in vivo. World J. Gastroenterol. 2006, 12, 4492–4497. [CrossRef]
130. Hulme, A.E.; Bogerd, H.P.; Cullen, B.R.; Moran, J.V. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 2007, 390,
199–205. [CrossRef]
131. Reddy, K.; Ooms, M.; Letko, M.; Garrett, N.; Simon, V.; Ndung’U, T. Functional characterization of Vif proteins from HIV-1
infected patients with different APOBEC3G haplotypes. AIDS 2016, 30, 1723–1729. [CrossRef]
132. Singh, K.K.; Wang, Y.; Gray, K.P.; Farhad, M.; Brummel, S.; Fenton, T.; Trout, R.; Spector, S.A. Genetic Variants in the Host
Restriction Factor APOBEC3G are Associated With HIV-1–Related Disease Progression and Central Nervous System Impairment
in Children. JAIDS J. Acquir. Immune Defic. Syndr. 2013, 62, 197–203. [CrossRef]
133. Do, H.; Vasilescu, A.; Diop, G.; Hirtzig, T.; Heath, S.C.; Coulonges, C.; Rappaport, J.; Therwath, A.; Lathrop, M.; Matsuda, F.; et al.
Exhaustive Genotyping of theCEM15 (APOBEC3G)Gene and Absence of Association with AIDS Progression in a French Cohort.
J. Infect. Dis. 2005, 191, 159–163. [CrossRef]
134. Valcke, H.S.; Bernard, N.F.; Bruneau, J.; Alary, M.; Tsoukas, C.M.; Roger, M. APOBEC3G genetic variants and their association
with risk of HIV infection in highly exposed Caucasians. AIDS 2006, 20, 1984–1986. [CrossRef]
135. De Maio, F.A.; Rocco, C.A.; Aulicino, P.C.; Bologna, R.; Mangano, A.; Sen, L. Effect of HIV-1 Vif variability on progression to
pediatric AIDS and its association with APOBEC3G and CUL5 polymorphisms. Infect. Genet. Evol. 2011, 11, 1256–1262. [CrossRef]
136. De Maio, F.A.; Rocco, C.A.; Aulicino, P.C.; Bologna, R.; Mangano, A.; Sen, L. APOBEC3-Mediated Editing in HIV Type 1 from
Pediatric Patients and Its Association withAPOBEC3G/CUL5Polymorphisms and Vif Variability. AIDS Res. Hum. Retrovir. 2012,
28, 619–627. [CrossRef]
137. Singh, H.; Marathe, S.; Nain, S.; Nema, V.; Angadi, M.; Bapat, S.; Pawar, J.; Ghate, M.; Sahay, S.; Gangakhedkar, R.R. Coding
region variant 186H/R in Exon 4 of APOBEC3G among individuals of Western India. APMIS 2016, 124, 401–405. [CrossRef]
138. Rathore, A.; Chatterjee, A.; Yamamoto, N.; Dhole, T.N.T.N. Absence of H186R Polymorphism in Exon 4 of the APOBEC3G Gene
among North Indian Individuals. Genet. Test. 2008, 12, 453–456. [CrossRef]
139. Reddy, K.; A Winkler, C.; Werner, L.; Mlisana, K.; Karim, S.A.; Ndung’U, T. APOBEC3G expression is dysregulated in primary
HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 2010, 24, 195–204. [CrossRef]
140. Compaore, T.R.; Soubeiga, S.T.; Ouattara, A.K.; Obiri-Yeboah, D.; Tchelougou, D.; Maiga, M.; Assih, M.; Bisseye, C.; Bakouan, D.;
Compaore, I.P.; et al. APOBEC3G Variants and Protection against HIV-1 Infection in Burkina Faso. PLoS ONE 2016, 11, e0146386.
[CrossRef]
141. Compaore, T.R.; Diarra, B.; Assih, M.; Obiri-Yeboah, D.; Soubeiga, S.T.; Ouattara, A.K.; Tchelougou, D.; Bisseye, C.; Bakouan, D.R.;
Compaore, I.P.; et al. HBV/HIV co-infection and APOBEC3G polymorphisms in a population from Burkina Faso. BMC Infect. Dis.
2016, 16, 336. [CrossRef] [PubMed]
Viruses 2021, 13, 1366 24 of 24
142. Bizinoto, M.C.; Leal, É.; Diaz, R.S.; Janini, L.M. Loci Polymorphisms of the APOBEC3G Gene in HIV Type 1-Infected Brazilians.
AIDS Res. Hum. Retrovir. 2011, 27, 137–141. [CrossRef] [PubMed]
143. Singh, H.; Gangakhedkar, R. Occurrence of APOBEC3G variations in West Indian HIV patients. Microb. Pathog. 2018, 121, 325–330.
[CrossRef] [PubMed]
144. Mhandire, K.; Duri, K.; Mhandire, D.; Musarurwa, C.; Stray-Pedersen, B.; Dandara, C. Evaluating the contribution of APOBEC3G
haplotypes, on influencing HIV infection in a Zimbabwean paediatric population. South. Afr. Med. J. 2016, 106, 119–123. [CrossRef]
145. Pace, C.; Keller, J.; Nolan, D.; James, I.; Gaudieri, S.; Moore, C.; Mallal, S. Population Level Analysis of Human Immunodeficiency
Virus Type 1 Hypermutation and Its Relationship with APOBEC3G and vif Genetic Variation. J. Virol. 2007, 81, 8843–8845.
[CrossRef]
146. Wang, X.; Abudu, A.; Son, S.; Dang, Y.; Venta, P.J.; Zheng, Y.-H. Analysis of Human APOBEC3H Haplotypes and Anti-Human
Immunodeficiency Virus Type 1 Activity. J. Virol. 2011, 85, 3142–3152. [CrossRef]
147. Oh Ainle, M.; Kerns, J.A.; Li, M.M.; Malik, H.S.; Emerman, M. Antiretroelement Activity of APOBEC3H Was Lost Twice in Recent
Human Evolution. Cell Host Microbe 2008, 4, 249–259. [CrossRef]
148. Chesarino, N.M.; Emerman, M. Polymorphisms in Human APOBEC3H Differentially Regulate Ubiquitination and Antiviral
Activity. Viruses 2020, 12, 378. [CrossRef]
149. Ooms, M.; Majdak, S.; Seibert, C.W.; Harari, A.; Simon, V. The Localization of APOBEC3H Variants in HIV-1 Virions Determines
Their Antiviral Activity. J. Virol. 2010, 84, 7961–7969. [CrossRef]
150. Gourraud, P.-A.; Karaouni, A.; Woo, J.; Schmidt, T.; Oksenberg, J.; Hecht, F.; Liegler, T.; Barbour, J. APOBEC3H haplotypes and
HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus–1 infection. Hum. Immunol. 2011,
72, 207–212. [CrossRef]
151. Binka, M.; Ooms, M.; Steward, M.; Simon, V. The Activity Spectrum of Vif from Multiple HIV-1 Subtypes against APOBEC3G,
APOBEC3F, and APOBEC3H. J. Virol. 2011, 86, 49–59. [CrossRef]
152. Ooms, M.; Letko, M.; Binka, M.; Simon, V. The Resistance of Human APOBEC3H to HIV-1 NL4-3 Molecular Clone Is Determined
by a Single Amino Acid in Vif. PLoS ONE 2013, 8, e57744. [CrossRef]
153. Benito, J.M.; Hillung, J.; Restrepo, C.; Cuevas, J.M.; Leon, A.; Ruiz-Mateos, E.; Palacios-Muñoz, R.; Górgolas, M.; Sanjuán, R.;
Rallón, N. Role of APOBEC3H in the Viral Control of HIV Elite Controller Patients. Int. J. Med. Sci. 2018, 15, 95–100. [CrossRef]
154. Sakurai, D.; Iwatani, Y.; Ohtani, H.; Naruse, T.K.; Terunuma, H.; Sugiura, W.; Kimura, A. APOBEC3H polymorphisms associated
with the susceptibility to HIV-1 infection and AIDS progression in Japanese. Immunogenetics 2015, 67, 253–257. [CrossRef]
155. Naruse, T.K.; Sakurai, D.; Ohtani, H.; Sharma, G.; Sharma, S.K.; Vajpayee, M.; Mehra, N.K.; Kaur, G.; Kimura, A. APOBEC3H
polymorphisms and susceptibility to HIV-1 infection in an Indian population. J. Hum. Genet. 2015, 61, 263–265. [CrossRef]
